Seneffe - Belgium, December 27, 2010, IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB) has announced today that it has acquired SonoTECH GmbH, a company active in software development for medical application.

Based in Neu-Ulm, Germany, SonoTECH was founded in 1996 and offers one main product range: Brachytherapy Treatment Planning Systems (TPS).

SonoTECH has developed a LDR (Low Dose Rate) and a HDR (High Dose Rate) brachytherapy treatment planning software.
n The LDR Brachytherapy Treatment Planning System, known as PSID (Permanent Seed Implant Dosimetry) for ultrasound guided radiation therapy of prostate cancer, uses advanced 3D visualization techniques allowing an overview of the planning results at unmatched speed and flexibility. PSID is used for treatment planning at numerous sites in Europe and around the world.
n The HDR Brachytherapy Treatment Planning System, known as HDRplusTM and FlexiplanTM, is an innovative and user friendly software equipped with a comprehensive set of optimization and evaluation features, for quick and efficient HDR planning.

The combination of the Treatment Planning technologies developed by SonoTECH with the LDR and HDR Brachytherapy products of IBt Bebig will provide the group with comprehensive solutions that will help to grow further its leading position in the brachytherapy market. In addition, IBt Bebig will be able to work with physicians in close cooperation to improve the functionality, planning quality and operability of the TPS.

The transaction will be effective as of December 31, 2010.

"The integration of SonoTECH team within IBt Bebig is an opportunity to bring key technologies in-house. Until now, IBt Bebig was selling its products including Treatment Planning Systems from SonoTECH. While now, we will strengthen our competitive advantages with the opportunity to further develop softwares to meet our customers' needs", said Dr. Edgar Löffler, Managing Director of IBt Bebig.

About IBt Bebig
... Contributing to saving lives!

The IBt Bebig group is a European based group, active in the Medical Device segment of the Health Care sector.

The core business of the IBt Bebig group is the cancer treatment by radiation technology. Its specificity is the treatment of cancer by brachytherapy, a technique which consists of placing a sealed medical device containing a minuscule quantity of a radioactive isotope in the body, on either a temporary or on a permanent basis. Depending on the application, the device can take the shape of a plaque, a seed or a catheter. The precise positioning of the device allows the cancer cells to be destroyed while sparing the healthy tissues and increasing the patient's quality of life. Today, the alternative brachytherapy procedures cover the non-invasive treatment of cancers of the prostate, neck, head and eye, as well as certain gynecological cancers.
IBt Bebig employs more than 150 people and has entities in Germany, France, United Kingdom, Spain, Italy and India. Its Head Office is located in Seneffe, Belgium and the company has been listed on the Euronext stock exchange since April 1997 (Reuters : IBTH.BR - Bloomberg : IBTB BB).